Publication
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (13)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 13
- cancerMalignant Ovarian Neoplasmcivic_curation1.00
- drugRucaparibcivic_curation1.00
- geneBRCA1civic_curation1.00
- geneBRCA2civic_curation1.00
- variantBRCA1 Mutationcivic_curation1.00
- variantBRCA1 Q1467*civic_curation1.00
- variantBRCA2 M1?civic_curation1.00
- variantBRCA2 M1Rcivic_curation1.00
- variantBRCA2 Mutationcivic_curation1.00
- variantBRCA2 R2336Pcivic_curation1.00
- variantBRCA2 V159Mcivic_curation1.00
- variantBRCA2 V211Icivic_curation1.00
- variantBRCA2 V211Lcivic_curation1.00
Curated evidence
Evidence citing this paper (11)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 27908594
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| BRCA1 Mutation2 | ||||||||
| Rucaparib | Malignant Ovarian Neoplasm | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID1897A phase 2 trial on patients with relapsed, platinum-sensitive high grade ovarian, fallopian tube or primary peritoneal carcinoma (ARIEL2 Part1, NCT01891344) was held to assess PARP inhibitor rucaparib… (full text at CIViC) PMID 27908594 · Swisher et al., 2017 · Open in CIViC | civic |
| 〃 | Malignant Ovarian Neoplasm | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID6341A phase 2 trial on patients with relapsed, platinum-sensitive high grade ovarian, fallopian tube or primary peritoneal carcinoma (ARIEL2 Part1, NCT01891344) was held to assess PARP inhibitor rucaparib… (full text at CIViC) PMID 27908594 · Swisher et al., 2017 · Open in CIViC | civic |
| BRCA1 Q1467*1 | ||||||||
| Rucaparib | Malignant Ovarian Neoplasm | Predictive | C | Supports Sensitivity Response | — | accepted | EID2878In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression … (full text at CIViC) PMID 27908594 · Swisher et al., 2017 · Open in CIViC | civic |
| BRCA2 M1?1 | ||||||||
| Rucaparib | Malignant Ovarian Neoplasm | Predictive | C | Supports Sensitivity Response | — | accepted | EID2880In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression … (full text at CIViC) PMID 27908594 · Swisher et al., 2017 · Open in CIViC | civic |
| BRCA2 M1R1 | ||||||||
| Rucaparib | Malignant Ovarian Neoplasm | Predictive | C | Supports Sensitivity Response | — | accepted | EID2879In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression … (full text at CIViC) PMID 27908594 · Swisher et al., 2017 · Open in CIViC | civic |
| BRCA2 Mutation2 | ||||||||
| Rucaparib | Malignant Ovarian Neoplasm | Predictive | B | Supports Sensitivity Response | 2 | accepted | EID2868A phase 2 trial on patients with relapsed, platinum-sensitive high grade ovarian, fallopian tube or primary peritoneal carcinoma (ARIEL2 Part1, NCT01891344) was held to assess PARP inhibitor rucaparib… (full text at CIViC) PMID 27908594 · Swisher et al., 2017 · Open in CIViC | civic |
| 〃 | Malignant Ovarian Neoplasm | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID6343A phase 2 trial on patients with relapsed, platinum-sensitive high grade ovarian, fallopian tube or primary peritoneal carcinoma (ARIEL2 Part1, NCT01891344) was held to assess PARP inhibitor rucaparib… (full text at CIViC) PMID 27908594 · Swisher et al., 2017 · Open in CIViC | civic |
| BRCA2 R2336P1 | ||||||||
| Rucaparib | Malignant Ovarian Neoplasm | Predictive | C | Supports Sensitivity Response | — | accepted | EID2884In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression … (full text at CIViC) PMID 27908594 · Swisher et al., 2017 · Open in CIViC | civic |
| BRCA2 V159M1 | ||||||||
| Rucaparib | Malignant Ovarian Neoplasm | Predictive | C | Supports Sensitivity Response | — | accepted | EID2881In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression … (full text at CIViC) PMID 27908594 · Swisher et al., 2017 · Open in CIViC | civic |
| BRCA2 V211I1 | ||||||||
| Rucaparib | Malignant Ovarian Neoplasm | Predictive | C | Supports Sensitivity Response | 4 | accepted | EID2883In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression … (full text at CIViC) PMID 27908594 · Swisher et al., 2017 · Open in CIViC | civic |
| BRCA2 V211L1 | ||||||||
| Rucaparib | Malignant Ovarian Neoplasm | Predictive | C | Supports Sensitivity Response | — | accepted | EID2882In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression … (full text at CIViC) PMID 27908594 · Swisher et al., 2017 · Open in CIViC | civic |